Colorectal Cancer Screening After Changes in US Preventive Services Task Force Guidelines With Increased Screening...

Area of Science:

• Gastroenterology
• Preventive Medicine
• Oncology

Background:

• In 2016, the USPSTF expanded recommended colorectal cancer screening options to include multitarget stool DNA and computed tomography colonography (CTC).
• These additions supplemented existing methods like fecal immunochemical test (FIT), sigmoidoscopy, and colonoscopy.
• The study aimed to analyze screening trends post-guideline update.

Purpose of the Study:

• To evaluate changes in colorectal cancer screening modalities following the 2016 USPSTF guideline revision.
• To assess the impact of newly recommended tests on the utilization of existing screening methods.
• To determine the effect on overall colorectal cancer screening rates.

Main Methods:

• A prospective study comparing colorectal cancer screening rates and test usage.
• Data collected for 6 months pre-guideline update and 30 months post-update.
• Analysis included multitarget stool DNA, colonoscopy, sigmoidoscopy, CTC, and FIT.

Main Results:

• Overall colorectal cancer screening rates showed no significant change (80.9% vs. 81.3%).
• Multitarget stool DNA screening significantly increased from 1.6% to 15.6%.
• Significant decreases were observed in CTC (3.8% to 1.5%), FIT (9.3% to 4.9%), and sigmoidoscopy (2.4% to 1.5%) usage.

Conclusions:

• The USPSTF guideline update did not increase overall colorectal cancer screening rates.
• Practice patterns shifted, with increased adoption of multitarget stool DNA testing.
• There was a notable decrease in the utilization of CTC, FIT, and sigmoidoscopy.